01 Aug 2012, BioSpectrum Bureau , BioSpectrum
Singapore: China Cord Blood Corporation (CCBC), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, filed its annual report on Form 20-F with the US Securities and Exchange Commission.
The filing included audited financial statements for the fiscal year ending March 31, 2012. The Form 20-F can be accessed at the US Securities and Exchange Commission's website and also be found at the investor relations section of CCBC's website. CCBC will provide a hard copy of the annual report, including a complete set of audited financial statements, free-of-charge to its shareholders upon request.
China Cord Blood recently reported a growth in revenue worth $15.8 million and also announced that it had repurchased 2,191,412 shares for $6.2 million in continuation with its share repurchase program.